15.55

5.57% +0.82

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is currently priced at $15.55, with a 24-hour trading volume of 496.16K. It has seen a +5.57% increased in the last 24 hours and a -6.61% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $14.86 pivot point. If it approaches the $15.60 resistance level, significant changes may occur.

Previous Close:

$14.73

Open:

$14.73

24h Volume:

496.16K

Market Cap:

$1.41B

Revenue:

$117.00M

Net Income/Loss:

$-307.00M

P/E Ratio:

-3.9268

EPS:

-3.96

Net Cash Flow:

$-330.00M

1W Performance:

+6.58%

1M Performance:

-6.61%

6M Performance:

-2.32%

1Y Performance:

-13.56%

1D Range:

$14.59

$15.62

52W Range:

$12.95

$25.47

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

510-694-6200

Address

3928 Point Eden Way, Hayward, CA

Employee

Twitter

@arcusbio

Next Earnings Date

2024-05-08

Latest SEC Filings

RCUS's Discussions on Twitter

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Navigating 5 Analyst Ratings For Arcus Biosciences

Benzinga

Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet

Zacks Investment Research

$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Benzinga

Arcus Biosciences Inc Stock (RCUS) Financials Data

Arcus Biosciences Inc (RCUS) Revenue 2024

RCUS reported a revenue (TTM) of $117.00 million for the quarter ending December 31, 2023, a +4.46% rise year-over-year.

Arcus Biosciences Inc (RCUS) Net Income 2024

RCUS net income (TTM) was -$307.00 million for the quarter ending December 31, 2023, a -14.98% decrease year-over-year.

Arcus Biosciences Inc (RCUS) Cash Flow 2024

RCUS recorded a free cash flow (TTM) of -$330.00 million for the quarter ending December 31, 2023, a -177.46% decrease year-over-year.

Arcus Biosciences Inc (RCUS) Earnings per Share 2024

RCUS earnings per share (TTM) was -$4.15 for the quarter ending December 31, 2023, a -11.56% decline year-over-year.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.